Has Joseph Gathe, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,910,059 in general payments to Joseph Gathe, MD across 1,676 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joseph Gathe, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joseph Gathe, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joseph Gathe, MD

Infectious Disease · Houston, TXNPI 1366436263

Payments from drug & device makers

$1,910,059in general payments, 2019–2025

Across 1,676 payments — averaging $1139.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$499K
Janssen Products, LP$346K
Beigene, Ltd.$332K
Janssen Research & Development, LLC$249K
Theratechnologies Inc.$197K
AbbVie$113K
plus $174K from 41 others

$30,082in research payments, 2019–2025

Across 12 payments — averaging $2506.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$15K
AbbVie$14K
Regeneron$1K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	456	$498,848
Janssen Products, LP	301	$346,284
Beigene, Ltd.	7	$332,128
Janssen Research & Development, LLC	32	$249,464
Theratechnologies Inc.	59	$197,217
AbbVie(2 entities)	162	$112,587
EMD Serono, Inc.	96	$81,162
Regeneron	7	$60,738
La Jolla Pharmaceutical Company	31	$12,245
Tetraphase Pharmaceuticals, Inc.	18	$10,054
Viiv Healthcare Company	103	$2,047
Johnson & Johnson(2 entities)	128	$1,830
Napo Pharmaceuticals Inc	59	$1,204
Merck	49	$981
Paratek Pharmaceuticals, Inc.	41	$884
Shionogi Inc	32	$699
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	20	$276
Axsome Therapeutics, Inc.	9	$207
Amarin Pharma, Inc.	10	$175
Lilly USA, LLC	7	$151
Esperion Therapeutics, Inc.	4	$74
Ferring Pharmaceuticals Inc.	3	$68
Novo Nordisk	3	$59
Arbor Pharmaceuticals, Inc.	4	$58
Melinta Therapeutics, LLC	4	$56
Antares Pharma, Inc.	3	$50
Genentech USA, Inc.	3	$39
Pfizer	2	$36
Eisai Inc.	1	$34
Pharming Healthcare, Inc.	2	$32
Tolmar, Inc.	2	$32
Cumberland Pharmaceuticals, Inc.	2	$31
Mayne Pharma Commercial LLC	2	$30
Microtransponder, Inc.	1	$30
Invivyd Inc	1	$29
Verity Pharmaceuticals Inc.	1	$24
Cormedix Inc.	1	$22
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$22
Aytu Biopharma, Inc.	1	$22
AstraZeneca	1	$20
Xeris Pharmaceuticals, Inc.	1	$20
Insmed, Inc.	1	$18
Currax Pharmaceuticals LLC	1	$16
Amgen	1	$16
Ortho Dermatologics, A Division Of Bausch Health US, LLC	1	$15
Nabriva Therapeutics, PLC	1	$13
Dynavax Technologies Corporation	1	$10

How this compares

$1,910,059 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas →

Medicare billing

Part B allowed, 2024

$365,540

Medicare patients

359

Services billed

3,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Houston

Eleftherios MylonakisHouston$6.4M
Roberto ArduinoHouston$2.1M
Issam RaadHouston$2M
Kevin GrimesHouston$1.9M
Jennifer WhitakerHouston$1.5M
Karen VigilHouston$1.4M
Roy ChemalyHouston$1.2M
David HuangHouston$884K
Luis OstroskyHouston$731K
Dimitrios KontoyiannisHouston$706K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →